PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 9, 2021

Primary Completion Date

August 16, 2021

Study Completion Date

November 30, 2021

Conditions
Coronary Artery Disease
Interventions
DRUG

Cangrelor

Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The duration of cangrelor/placebo infusion will be 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase

DRUG

Placebo

Normal saline will be infused for 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase

Trial Locations (1)

32209

University of Florida Jacksonville, Jacksonville

All Listed Sponsors
collaborator

Scott R. MacKenzie Foundation

OTHER

lead

University of Florida

OTHER

NCT04634162 - PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment | Biotech Hunter | Biotech Hunter